• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关于用于腹腔内治疗的磷酸铬(32P)悬浮液腹腔内分布的观察

Observations on the intraperitoneal distribution of chromic phosphate (32P) suspension for intraperitoneal therapy.

作者信息

Sullivan D C, Harris C C, Currie J L, Wilkinson R H, Creasman W T

出版信息

Radiology. 1983 Feb;146(2):539-41. doi: 10.1148/radiology.146.2.6849103.

DOI:10.1148/radiology.146.2.6849103
PMID:6849103
Abstract

Seven patients received intraperitoneal chromic phosphate (32P) suspension in a 3-ml bolus with a saline flush, and another ten patients were given the suspension in a 500-ml infusion of normal saline. During the first six hours after administration, most 32P activity redistributed to the gravity-dependent portion of the peritoneal cavity. From 24 hours up to seven weeks after administration, activity distributions were fixed. Dispersions were heterogeneous in every patient, but the most marked examples of localized activity occurred in patients who had received bolus injections. We concluded that large-volume infusions and frequent changes in patient position for several hours following the infusion, contribute to improved dispersion of 32P suspension.

摘要

7名患者接受了3毫升大剂量腹腔内注射含生理盐水冲洗的磷酸铬(32P)混悬液,另外10名患者接受了在500毫升生理盐水中输注该混悬液的治疗。给药后的前6小时内,大部分32P活性重新分布至腹腔的重力依赖部分。给药后24小时直至7周,活性分布固定。每位患者的分布均不均匀,但局部活性最显著的例子发生在接受大剂量注射的患者中。我们得出结论,大容量输注以及输注后数小时内频繁改变患者体位,有助于改善32P混悬液的分散。

相似文献

1
Observations on the intraperitoneal distribution of chromic phosphate (32P) suspension for intraperitoneal therapy.关于用于腹腔内治疗的磷酸铬(32P)悬浮液腹腔内分布的观察
Radiology. 1983 Feb;146(2):539-41. doi: 10.1148/radiology.146.2.6849103.
2
Pleuroperitoneal migration of intraperitoneal phosphorus-32-chromic phosphate therapy for stage I ovarian carcinoma.用于I期卵巢癌治疗的腹腔内32磷-磷酸铬的胸膜腔迁移
J Nucl Med. 1996 Apr;37(4):636-9.
3
Intraperitoneal distribution imaging prior to chromic phosphate (P-32) therapy in ovarian cancer patients.卵巢癌患者接受磷酸铬(P-32)治疗前的腹腔分布成像。
Clin Nucl Med. 1994 Jan;19(1):43-8. doi: 10.1097/00003072-199401000-00012.
4
Peritoneoscintigraphy in detection of improper placement of peritoneal catheter into bowel lumen prior to chromic phosphate P-32 therapy. A case report.在磷酸铬P-32治疗前,腹膜闪烁显像术用于检测腹膜导管误置入肠腔。病例报告。
Clin Nucl Med. 1985 Nov;10(11):777-9. doi: 10.1097/00003072-198511000-00005.
5
Distribution and tissue dose of intraperitoneally administered radioactive chromic phosphate (32P) in New Zealand white rabbits.
Radiology. 1980 Mar;134(3):729-34. doi: 10.1148/radiology.134.3.7355227.
6
Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging.早期卵巢癌女性患者在全面手术分期后采用腹腔内注射磷酸铬(32P)进行辅助治疗。
Obstet Gynecol. 1992 Jun;79(6):993-7.
7
Intracavitary chromic phosphate (32P) colloidal suspension therapy.腔内磷酸铬(32P)胶体悬浮液疗法。
Cancer. 1981 Dec 15;48(12):2596-8. doi: 10.1002/1097-0142(19811215)48:12<2596::aid-cncr2820481210>3.0.co;2-j.
8
Intraperitoneal chromic phosphate therapy after second-look laparotomy for ovarian cancer.卵巢癌二次探查剖腹术后的腹腔内磷酸铬治疗
Cancer. 1988 Mar 1;61(5):919-27. doi: 10.1002/1097-0142(19880301)61:5<919::aid-cncr2820610511>3.0.co;2-p.
9
Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging.腹膜内注射磷酸铬P 32作为手术分期后持续性卵巢癌的挽救治疗。
Am J Obstet Gynecol. 1987 May;156(5):1153-8. doi: 10.1016/0002-9378(87)90131-1.
10
Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits.
Gynecol Oncol. 1989 Mar;32(3):314-8. doi: 10.1016/0090-8258(89)90631-8.

引用本文的文献

1
SPECT using Bremsstrahlung to quantify 90Y uptake in Baker's cysts: its application in radiation synovectomy of the knee.利用轫致辐射的单光子发射计算机断层扫描(SPECT)定量检测贝克囊肿中钇-90的摄取:其在膝关节放射性滑膜切除术中的应用
Eur J Nucl Med. 1988;14(9-10):498-503. doi: 10.1007/BF00252396.
2
Radionuclide therapy revisited.放射性核素治疗再探讨。
Eur J Nucl Med. 1991;18(6):408-31. doi: 10.1007/BF02258432.